uBiome Appoints Dr. Aubrey Tauer, Veterinary Epidemiologist, to its Scientific Advisory Board

Share Article

The leader in microbial genomics appoints board-certified specialist in population medicine and public health to its board of scientific advisors.

“I have had very interesting conversations with [uBiome's] Research and Development department and am thrilled to be able to contribute using comparative species approaches and furthering understanding of the roles of zoonotic microbes and contact with animals to the human microbiome.” - Dr. Tauer

uBiome, the leader in microbial genomics, announces the addition of Dr. Aubrey Tauer, DVM, MPH, DACVPM, Founder and President of Cūra Earth, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Tauer will bring to uBiome a diverse background in veterinary public health, disease ecology, and microbiology. The appointment will help uBiome continue its advancement in human microbiome research.

“There are parallels between Dr. Tauer’s work on the animal microbiome and zoonotic diseases and uBiome’s increasing focus on the microbiome and its connection to human health,” Jessica Richman, PhD, co-founder and CEO of uBiome, said. “For that reason and more, we are thrilled to have Dr. Tauer join the uBiome Scientific Advisory Board.”

Dr. Tauer completed her Doctorate in Veterinary Medicine at the University of Minnesota-Twin Cities. In 2011, Dr. Tauer founded Cūra Earth, a non-profit organization dedicated to research, development, and education at the intersection of global animal, human, and environmental health. As Head Veterinarian at AnimalBiome, she consults on microbiome testing and fecal transplant pills for pets of all kinds. She also serves as a freelance medicine and science writer, covering a range of topics including veterinary medicine, public health, microbiome science, and ecology/conservation biology, in addition to curriculum development.

About joining uBiome's Scientific Advisory Board, Dr. Tauer said, “I have been fascinated by microbial ecology and the many research questions and applied intervention possibilities, and uBiome has swiftly become the leader in human diagnostics in this field. I have had very interesting conversations with their Research and Development department and am thrilled to be able to contribute using comparative species approaches and furthering understanding of the roles of zoonotic microbes and contact with animals to the human microbiome.”

In addition to Dr. Tauer, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

uBiome Public Relations
Follow >
Visit website